Upgrade to SI Premium - Free Trial

BioCryst Pharma (BCRX)

7.75 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/4/26)

Latest Headlines

BioCryst to Report Third Quarter 2026 Financial Results on November 4 October 21, 2026 4:01 PM - Globe NewsWire FDA approves Orladeyo pellet form for adults and adolescents with HAE October 21, 2026 7:02 AM - StreetInsider BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE October 21, 2026 7:00 AM - Globe NewsWire BioCryst forms seven-member scientific advisory board October 5, 2026 7:00 AM - StreetInsider BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth October 5, 2026 7:00 AM - Globe NewsWire BioCryst Pharma (BCRX) PT Raised to $13 at JPMorgan September 30, 2026 9:09 AM - StreetInsider RBC Capital Downgrades BioCryst Pharma (BCRX) to Sector Perform September 10, 2026 5:11 AM - StreetInsider TD Cowen Starts BioCryst Pharma (BCRX) at Buy September 8, 2026 10:26 AM - StreetInsider Japan approves BioCryst's Orladeyo for children ages 2 to 12 with HAE August 25, 2026 7:02 AM - StreetInsider BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan August 25, 2026 7:01 AM - Globe NewsWire Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P. August 14, 2026 4:48 PM - SEC Filing Form SCHEDULE 13G BIOCRYST PHARMACEUTICALS Filed by: STATE STREET CORP August 7, 2026 8:56 AM - SEC Filing BioCryst Pharma (BCRX) PT Lowered to $13 at RBC Capital August 6, 2026 6:43 AM - StreetInsider Form S-8 BIOCRYST PHARMACEUTICALS August 5, 2026 4:25 PM - SEC Filing Form 10-Q BIOCRYST PHARMACEUTICALS For: Jun 30 August 5, 2026 4:05 PM - SEC Filing BioCryst Pharma (BCRX) PT Lowered to $20 at Wedbush August 5, 2026 12:40 PM - StreetInsider BioCryst Pharma (BCRX) Tops Q2 EPS by 14c August 5, 2026 7:22 AM - StreetInsider Form 8-K BIOCRYST PHARMACEUTICALS For: Aug 05 August 5, 2026 7:03 AM - SEC Filing BioCryst Reports Second Quarter 2026 Financial Results August 5, 2026 7:00 AM - Globe NewsWire Form 8-K/A BIOCRYST PHARMACEUTICALS For: Jun 25 August 4, 2026 7:01 AM - SEC Filing Full Article List